-
DiscoveryProbe™ FDA-approved Drug Library: Enabling Mecha...
2025-10-25
Explore how the DiscoveryProbe™ FDA-approved Drug Library empowers precision drug discovery through mechanism-guided high-throughput screening, with unique insight into CYP3A4 selectivity. Discover advanced strategies for pharmacological target identification and drug repositioning across cancer and neurodegenerative research.
-
A 83-01: Precision ALK-5 Inhibitor for Organoid & EMT Res...
2025-10-24
A 83-01, a selective TGF-β type I receptor inhibitor, empowers researchers to streamline organoid modeling, enhance EMT studies, and achieve robust Smad-dependent transcription suppression. Learn how this ALK-5 inhibitor outperforms conventional reagents in cellular growth inhibition, troubleshooting, and advanced disease modeling applications.
-
A 83-01: Selective TGF-β Inhibition for EMT & Organoid Mo...
2025-10-23
A 83-01 redefines selective TGF-β type I receptor inhibition, powering advanced models of epithelial-mesenchymal transition (EMT), cellular growth suppression, and organoid fidelity. Its robust performance and versatile solubility profile enable reproducible workflows in cancer, fibrosis, and stem cell research.
-
A 83-01: Precision TGF-β Pathway Inhibition for Dynamic O...
2025-10-22
Explore how A 83-01, a selective TGF-β type I receptor inhibitor, enables tunable control of human organoid self-renewal and differentiation. This in-depth analysis reveals advanced strategies and mechanistic insights for EMT, cancer, and fibrosis research.
-
A 83-01: Precision Inhibition of TGF-β Signaling for Stem...
2025-10-21
Explore how A 83-01, an advanced ALK-5 inhibitor, uniquely enables targeted TGF-β signaling pathway inhibition for in-depth stemness, EMT, and liver regeneration studies. Discover novel mechanistic insights and translational potential beyond conventional applications.
170 records 12/12 page Previous First page 上5页 1112